Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Clinical trial NCT06995677 · RECRUITING

Trial details

NCT number: NCT06995677
Sponsor: Tyra Biosciences, Inc
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Low-grade NMIBC FGFR Gene Amplification FGFR Gene Alterations FGFR3 Gene Alteration FGFR3 Gene Mutation FGFR3 Gene Fusions

Start date: 2025-06-27
Primary completion: 2028-02-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.